Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for pulmonary protection after total knee replacement in elderly patients
ChiCTR2200060827Phase 4Not yet recruiting
- Sponsor
- The Third Hospital of Hebei Medical University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine in not applicable; "lung injury" is not a specific disease (3 arms), sponsored by The Third Hospital of Hebei Medical University. Primary endpoints: Endothelin-1 and Nitric oxide. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
not applicable; "lung injury" is not a specific disease
Beyond the preview
Go deeper on ChiCTR2200060827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060827.